TY  - JOUR
T1  - Anti-Proliferation of MDA-MB-231 Human Breast Tumour Cells by Arsenic Trioxide via Induction of Apoptosis
AU - , Lin-Li Zhou AU - , Judy Yuet-Wa Chan AU - , Jun Wang AU - , Kwok-Pui Fung 
JO  - Research Journal of Medical Sciences
VL  - 2
IS  - 5
SP  - 236
EP  - 243
PY  - 2008
DA  - 2001/08/19
SN  - 1815-9346
DO  - rjmsci.2008.236.243
UR  - https://makhillpublications.co/view-article.php?doi=rjmsci.2008.236.243
KW  - Arsenic trioxide
KW  -breast tumour
KW  -MDA-MB-231
KW  -apoptosis
AB  - Arsenic Trioxide (As<SUB>2</SUB>O<SUB>3</SUB>) has been explored for its use as medicine in both Western and Chinese societies. In 1990s, As<SUB>2</SUB>O<SUB>3</SUB> was reported to treat patients with acute promyelocytic leukemia (APL). Until recently, research on other solid tumour cells was emerged. In the present study, the mechanism of As<SUB>2</SUB>O<SUB>3</SUB> treatment of human breast tumour MDA-MB-231 cells was investigated. It was found that As<SUB>2</SUB>O<SUB>3</SUB> inhibited the cell proliferation of MDA-MB-231 cells in a time- and dose-dependent manner. Mechanistic study indicated that the inhibition was induced via cell cycle arrest and apoptosis. As<SUB>2</SUB>O<SUB>3</SUB> induced apoptosis via both extrinsic and intrinsic apoptotic pathways by regulating the pro- or anti-apoptotic molecules. Moreover, As<SUB>2</SUB>O<SUB>3</SUB>-induced cell cycle arrested at G<SUB>2</SUB> phase in MDA-MB-231 cells. The study revealed that As<SUB>2</SUB>O<SUB>3</SUB> was a potent candidate for further investigation for combating against human breast tumour including the late stage breast tumour.
ER  -